[go: up one dir, main page]

AR120936A1 - Anticuerpos anti-cd73 y usos de estos - Google Patents

Anticuerpos anti-cd73 y usos de estos

Info

Publication number
AR120936A1
AR120936A1 ARP200103688A ARP200103688A AR120936A1 AR 120936 A1 AR120936 A1 AR 120936A1 AR P200103688 A ARP200103688 A AR P200103688A AR P200103688 A ARP200103688 A AR P200103688A AR 120936 A1 AR120936 A1 AR 120936A1
Authority
AR
Argentina
Prior art keywords
antibodies
vectors
cells
methods
nucleic acids
Prior art date
Application number
ARP200103688A
Other languages
English (en)
Inventor
Horacio G Nastri
Shaun M Stewart
Juan Carlos Almagro
Jing Zhou
Rebecca A Buonpane
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR120936A1 publication Critical patent/AR120936A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos anti-CD73. También se describen ácidos nucleicos, vectores, células y composiciones farmacéuticas relacionados. También se describen métodos para tratar el cáncer con los anticuerpos anti-CD73.
ARP200103688A 2020-01-03 2020-12-30 Anticuerpos anti-cd73 y usos de estos AR120936A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062956847P 2020-01-03 2020-01-03

Publications (1)

Publication Number Publication Date
AR120936A1 true AR120936A1 (es) 2022-03-30

Family

ID=74347717

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103688A AR120936A1 (es) 2020-01-03 2020-12-30 Anticuerpos anti-cd73 y usos de estos

Country Status (19)

Country Link
US (2) US12018089B2 (es)
EP (1) EP4084825A1 (es)
JP (1) JP2023509448A (es)
KR (1) KR20220121850A (es)
CN (1) CN115135341A (es)
AR (1) AR120936A1 (es)
AU (1) AU2020417804A1 (es)
BR (1) BR112022013236A2 (es)
CA (1) CA3166533A1 (es)
CL (2) CL2022001769A1 (es)
CO (1) CO2022009248A2 (es)
CR (1) CR20220317A (es)
EC (1) ECSP22051701A (es)
IL (1) IL294436A (es)
MX (1) MX2022007575A (es)
PE (1) PE20221409A1 (es)
PH (1) PH12022551636A1 (es)
TW (1) TWI873265B (es)
WO (1) WO2021138467A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
AR120936A1 (es) 2020-01-03 2022-03-30 Incyte Corp Anticuerpos anti-cd73 y usos de estos
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
WO2022147092A1 (en) * 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
CN113025567A (zh) * 2021-03-31 2021-06-25 中国人民解放军陆军特色医学中心 一种椎间盘单细胞的分离方法
WO2023060276A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Compositions and methods for detecting cadherin-17 protein
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025025190A1 (zh) * 2023-08-03 2025-02-06 贝达药业股份有限公司 抗cd73抗体及其应用
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US20020009444A1 (en) 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
SI1613350T1 (sl) 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
JP2008540678A (ja) 2005-05-18 2008-11-20 バイオジェン アイデック インク． 線維形成状態の治療方法
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
KR102536786B1 (ko) 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Ｃｄ７３ 차단
HUE054339T2 (hu) * 2014-11-10 2021-08-30 Medimmune Ltd CD73-ra specifikus kötõmolekulák és alkalmazásaik
US20160129108A1 (en) * 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
SG10201913004UA (en) * 2014-11-21 2020-03-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
EP3259288A1 (en) 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CN109154611B (zh) 2015-12-09 2022-04-08 科尔沃斯制药股份有限公司 人源化抗cd73抗体
KR20230038311A (ko) * 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP3481869A4 (en) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
MX392340B (es) 2016-12-13 2025-03-21 Astellas Pharma Inc Anticuerpo anti cd73 humana.
EP3383916B1 (en) 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
CA3063344A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Novel cd73 antibody, preparation and uses thereof
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
MX2020009394A (es) * 2018-03-09 2021-01-15 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos.
KR102804816B1 (ko) * 2018-03-09 2025-05-09 페인스 테라퓨틱스 인코포레이티드 항-cd73 항체 및 이의 용도
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
EP3773714A1 (en) 2018-04-12 2021-02-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
MX2021005248A (es) 2018-11-05 2021-08-11 Corvus Pharmaceuticals Inc Anticuerpos contra cd73 activadores de células b.
KR20210093255A (ko) 2018-11-12 2021-07-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd73 항체, 이의 항원 결합 단편 및 이의 적용
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN111499747B (zh) 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
JP7623706B2 (ja) 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｃｄ７３に特異的な結合分子と結合分子の使用
CN112111008B (zh) 2019-06-19 2024-04-30 海正生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
JP7471016B2 (ja) 2019-08-21 2024-04-19 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド 抗ｃｄ７３抗体およびその適用
JP7631317B2 (ja) 2019-08-26 2025-02-18 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのトリアゾロピリミジン
US11634500B2 (en) 2019-09-06 2023-04-25 Les Laboratoires Servier Anti-CD73 antibodies and compositions
WO2021087463A1 (en) 2019-11-01 2021-05-06 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
JP7789667B2 (ja) 2019-11-15 2025-12-22 ジェンザイム・コーポレーション 二重パラトープ性ｃｄ７３抗体
CA3165384A1 (en) 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
AR120936A1 (es) 2020-01-03 2022-03-30 Incyte Corp Anticuerpos anti-cd73 y usos de estos
JP2023521362A (ja) 2020-04-09 2023-05-24 エイプリルバイオ カンパニー リミテッド Ｃｄ７３免疫チェックポイントを抑制するためのモノクローナル抗体及びその抗原結合断片並びにその使用
JP2023522365A (ja) 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用
AU2020447878A1 (en) 2020-05-12 2023-02-02 Biotheus Inc. Anti-CD73 antibody and use thereof
EP4159763A4 (en) 2020-05-29 2024-06-12 BrightPath Biotherapeutics Co., Ltd. ANTI-CD73 ANTIBODIES AND USE THEREOF
CN115734972A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies

Also Published As

Publication number Publication date
ECSP22051701A (es) 2022-08-31
US12018089B2 (en) 2024-06-25
CA3166533A1 (en) 2021-07-08
PE20221409A1 (es) 2022-09-20
CN115135341A (zh) 2022-09-30
TWI873265B (zh) 2025-02-21
EP4084825A1 (en) 2022-11-09
US20210230293A1 (en) 2021-07-29
CL2024002235A1 (es) 2024-12-27
US20240352143A1 (en) 2024-10-24
AU2020417804A1 (en) 2022-07-21
CR20220317A (es) 2022-09-02
IL294436A (en) 2022-09-01
BR112022013236A2 (pt) 2022-09-06
TW202128768A (zh) 2021-08-01
CO2022009248A2 (es) 2022-08-19
CL2022001769A1 (es) 2023-01-20
WO2021138467A1 (en) 2021-07-08
MX2022007575A (es) 2022-09-23
KR20220121850A (ko) 2022-09-01
JP2023509448A (ja) 2023-03-08
PH12022551636A1 (en) 2024-01-08

Similar Documents

Publication Publication Date Title
CO2022009248A2 (es) Anticuerpos anti-cd73 y usos de estos
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
AR115389A1 (es) Anticuerpo antagonista de cd73
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
UY37635A (es) Anticuerpos anti phf-tau y sus usos
BR112022005114A2 (pt) Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2021012003A (es) Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
ECSP22014455A (es) Anticuerpos anti-cd96 y sus métodos de uso
CO2024009042A2 (es) Anticuerpos anti-calreticulina (calr) mutante y usos de estos
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2020012788A (es) Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso.
CO2023010689A2 (es) Anticuerpos y usos de estos
CO2021007444A2 (es) Anticuerpos antiperiostina y usos de estos
CO2024015896A2 (es) Inhibidores de mek y usos de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
CO2023016037A2 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.
BR112019004017A2 (pt) proteínas quiméricas para direcionar dsrna
AR127891A1 (es) Anticuerpos anti-calreticulina (calr) mutante y usos de estos